Search

Background elevated systolic blood pressure (sBP) after mechanical thrombectomy (MT) correlates with worse outcome. however, the association between sBP reduction (sBPr) and outcome after successful reperfusion with MT is not well established. Objective To investigate the association between sBPr in the first 24 hours after successful reperfusion and the functional and safety outcomes of MT. Methods a multicenter retrospective study, which included 10 comprehensive stroke centers, was carried out. Patients with acute ischemic stroke and anterior circulation large vessel occlusions who achieved successful reperfusion via MT were included. SBPr was calculated using the formula 100x([admission SBP-mean sBP]/admission SBP). Poor outcome was defined as a modified rankin scale (mrs) score of 3-6 at 90 days. safety endpoints included symptomatic intracerebral hemorrhage, mortality, and requirement for hemicraniectomy during admission. a generalized mixed linear model was used to study the association between sBPr and outcomes. results a total of 1361 patients were included in the final analysis. sBPr as a continuous variable was inversely associated with poor outcome (Or=0.97; 95% ci 0.95 to 0.98; p<0.001) but not with the safety outcomes. subanalysis based on reperfusion status showed that sBPr was associated with lower odds of poor outcome only in patients with complete reperfusion (modified Thrombolysis in cerebral infarction (mTici 3)) but not in patients with incomplete reperfusion (mTici 2b). When sBPr was divided into categories (<1%, 1%-10%, 11%-20%, >20%), the rate of poor outcome was highest in the first group. Conclusion SBPr in the first 24 hours after successful reperfusion was inversely associated with poor outcome. no association between sBPr and safety outcome was found. [ABSTRACT FROM AUTHOR]

Background: Atrial fibrillation (AF) associated ischemic stroke is associated with worse functional outcomes, less effective recanalization, and increased rates of hemorrhagic complications after intravenous thrombolysis (IVT). Conversely, AF is not associated with hemorrhagic complications or functional outcomes in patients undergoing mechanical thrombectomy (MT). This differential effect of MT and IVT in AF associated stroke raises the question of whether bridging thrombolysis increases hemorrhagic complications in AF patients undergoing MT., Methods: This international cohort study of 22 comprehensive stroke centers analyzed patients with large vessel occlusion (LVO) undergoing MT between June 1, 2015 and December 31, 2020. Patients were divided into four groups based on comorbid AF and IVT exposure. Baseline patient characteristics, complications, and outcomes were reported and compared., Results: 6461 patients underwent MT for LVO. 2311 (35.8%) patients had comorbid AF. In non-AF patients, bridging therapy improved the odds of good 90 day functional outcomes (adjusted OR (aOR) 1.29, 95% CI 1.03 to 1.60, p=0.025) and did not increase hemorrhagic complications. In AF patients, bridging therapy led to significant increases in symptomatic intracranial hemorrhage and parenchymal hematoma type 2 (aOR 1.66, 1.07 to 2.57, p=0.024) without any benefit in 90 day functional outcomes. Similar findings were noted in a separate propensity score analysis., Conclusion: In this large thrombectomy registry, AF patients exposed to IVT before MT had increased hemorrhagic complications without improved functional outcomes, in contrast with non-AF patients. Prospective trials are warranted to assess whether AF patients represent a subgroup of LVO patients who may benefit from a direct to thrombectomy approach at thrombectomy capable centers., Competing Interests: Competing interests: RMS: consulting and teaching agreements with Penumbra, Abbott, Medtronic, InNeuroCo, and Cerenovus. MNP: travel grants/honoraria from Phenox, Stryker, and Siemens. ASA: consultant for Balt, Johnson and Johnson, Leica, Medtronic, Microvention, Penumbra, Scientia, Siemens, and Stryker; research support for Cerenovus, Microvention, Penumbra, and Siemens; and shareholder of Bendit, Cerebrotech, Endostream, Magneto, Marblehead, Neurogami, Serenity, Synchron, Triad Medical, and Vascular Simulations. LE: consultant for Balt, Cerenovuc, Medtronic, MicroVention, Penumbra, Sequent, and Stryker; and research support for Siemens. PJ: consultant for Medtronics and Microvention. AMS: consultant for Penumbra, Microvention, and Pulsar Vascular; and travel grants/honoraria from Penumbra, Pulsar Vascular, Microvention, and Stryker. KMF, JM, PK, and RDL are on the editorial board of Journal of Neurointerventional Surgery., (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)